DEINOVE has built a strong network of academic, industrial and institutional collaborations and intends to continue in this way to meet the global challenge of antibiotic resistance, a major health threat.
Academic collaborations
|
|
|
| Institut Charles Viollette (ICV) is a partner of the AGIR program for its expertise in enzymatic engineering and characterization. | Collaboration with the Süssmuth Group (Technical University of Berlin) for the characterization of DNB101 and the study of biosynthetic pathways |
DEINOVE is also supported by a large number of clinicians from the Georges Pompidou, Lariboisière, Cologne University, and other hospitals to advance its research.
Industrial collaborations
|
|
||
| Llicense option agreement with REDX PHARMA (British biopharma) regarding the NTBI preclinical program for novel antibiotics | Exclusive research license with Naicons (Italian biopharma) to explore part of their collection of microbial strains, as part of the AGIR program. | Collaboration with bioMérieux, a leading specialist in in vitro diagnostics, providing exclusive strains for DEINOVE to research novel antibiotics as part of the AGIR program. |
Institutional support
Non-dilutive financial support provided by public or private institutions has been a key element of DEINOVE's development strategy since its inception. In its antibiotic activities, DEINOVE has benefited from:
|
|
|
|
|
Support for the launch of the DEINOBIOTICS program.
|
Support for the financing of the AGIR program. |
Support for the labelling of the AGIR program. |
